Perakizumab, currently Novan, presents a exciting step in the fight against multiple chronic illnesses. Distinct from current therapies, this antibody selectively targets blocks the beta-TGF signaling, a key factor in https://bookmarklinking.com/story11254588/perakizumab-a-new-treatment-for-fibrosis-conditions